Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 4/26/23 → 4/25/26 |
Funding
- BeiGene USA Incorporated: $25,818.00
22-GI-130-BG-PMC (LAG-3): A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy in Patien
- Nutalapati, Snigdha (PI)